Interestingly, CKD patients in PD therapy presented elevated plasmatic concentrations of malondialdehyde and upregulated gene and protein expressions of NRF2 and SOD2 compared to healthy subjects, suggesting the important contribution of the NRF2/oxidative-stress pathway in peritoneal damage [84]. The gene discussed is SOD2; the disease is chronic kidney disease.